Mirati Therapeutics, Inc. (MRTX)

$51.29

+0.23 (+0.45%)
Rating:
Recommendation:
Neutral
Symbol MRTX
Price $51.29
Beta 0.970
Volume Avg. 1.95M
Market Cap 2.954B
Shares () -
52 Week Range 32.96-124.81
1y Target Est -
DCF Unlevered MRTX DCF ->
DCF Levered MRTX LDCF ->
ROE -60.52% Strong Sell
ROA -56.75% Strong Sell
Operating Margin -
Debt / Equity 15.41% Neutral
P/E -
P/B 2.55 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest MRTX news


Dr. Charles Baum
Healthcare
Biotechnology
NASDAQ Global Select

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.